ArticleBMC women's health2025
Breast carcinoma in a patient with neurofibromatosis type 1 and huge plexiform neurofibroma of the contralateral breast: a case report.
Article in BMC women's health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Circulating Tumor DNA in Neurofibromatosis Type 1: Translating Molecular Discovery into Clinical Surveillance.Diagnostics (Basel, Switzerland) · 2026Review
- Early-stage HER2-positive breast cancer in neurofibromatosis type 1: a case report with literature review.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNeurofibromatosis type 1 (NF1) is a genetic disorder associated with an increased risk of various cancers, including breast cancer. This report presents a case of a patient with NF1 who had a huge plexiform neurofibroma of the right breast and developed invasive carcinoma in the left breast. CASE PRESENTATION: A woman with a known history of NF1, enlarged right breast, and pectus carinatum presented with locally advanced breast cancer of the left breast. The patient underwent four cycles of neoadjuvant chemotherapy with doxorubicin and cyclophosphamide, followed by a left modified radical mastectomy and axillary lymph node dissection. Postoperative pathology showed a complete pathological response. Subsequently, the patient received four cycles of adjuvant paclitaxel followed by endocrine therapy with anastrozole which was replaced by tamoxifen due to bone and muscle pain. At one year follow-up, the patient remains free of disease. The patient was referred to a plastic surgeon for resection of the enlarged right breast.
conclusionIt is known that women with NF1 have a higher risk of developing breast cancer, as demonstrated in our case. These patients could benefit from an early start of breast cancer screening, which could lead to an early diagnosis of early-stage tumors and a better prognosis. Additionally, enhanced access to healthcare centers and intensive surveillance could contribute significantly to better outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.